Evaluation of stem/stromal cell transplantation safety and efficacy in children diagnosed with cerebral palsy: A systematic review and meta-analysis of randomized controlled trials
Fatahi R., Heydarpour F., Motlagh SM., Mansouri K.
Meta-analysis, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Meta-analysis
- Journal
- Stem Cell Res Ther (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40877893
- PMCID
- PMC12395659
- DOI
- 10.1186/s13287-025-04550-9
Abstract (original English)
Background Cerebral palsy is a neurological disorder that affects both postnatal and prenatal children. It results from brain damage in the cerebral motor cortex. The three types of CP are spastic, dyskinetic, and mixed forms. This study aims to evaluate the efficacy and safety of stem or stromal cell therapy in children diagnosed with cerebral palsy. A systematic search was conducted across four databases: PubMed, ISI Web of Science, Scopus, and Embase from inception to August 23, 2024, to identify studies evaluating the efficacy and safety of stem cell therapy for cerebral palsy. Data extraction was performed for all randomized controlled clinical studies. ROB2 (Risk of Bias Tool 2) was used to assess the risk of bias in the included studies. The main outcome measures were extracted from each study for meta-analysis, and a PRISMA flow diagram was used to illustrate the study selection process. Eventually, thirteen studies met the inclusion criteria. The Gross Motor Function Measure (GMFM) is crucial for assessing motor function changes and evaluating the impact of stem cell therapy. Subgroup analysis of GMFM scores were conducted based on assessment time points (3, 6, and 12 months post-treatment), route of administration, and type of stem cell used. The results demonstrate that stem cell therapy remarkably improved GMFM score in the treatment group. For safety analysis, adve
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.